4-[alpha-(4-cyanophenyl)-1-(1,3,4-triazolyl)-methyl]-benzonitrile

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 4-[alpha-(4-cyanophenyl)-1-(1,3,4-triazolyl)-methyl]-benzonitrile
• 英文别名: 4-[(4-cyanophenyl)-(1H-1,2,4-triazol-5-yl)methyl]benzonitrile
• 化学式: C₁₇H₁₁N₅
• 分子量: 285.308
• InChiKey: IIZUMTBKXIGSNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  89.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[alpha-(4-cyanophenyl)-1-(1,3,4-triazolyl)-methyl]-benzonitrile 生成 4-[(4-氰基苯基)-氟-(1,2,4-三唑-1-基)甲基]苯甲腈
  参考文献：
  名称：

  .alpha.-fluoro-.alpha.-(1,2,3-triazolyl)-phenylmethyl derivatives useful

  摘要：

  式I的化合物##STR1##其中Z、R、R.sub.1、R.sub.2和X如描述中所定义，具有有价值的药物特性，尤其对抗肿瘤有效。它们的制备方法已经是众所周知的。

  公开号：

  US05376669A1
• 作为产物：
  描述：

  4-[1-(1,3,4-triazolyl)methyl]-benzonitrile 生成 4-[alpha-(4-cyanophenyl)-1-(1,3,4-triazolyl)-methyl]-benzonitrile
  参考文献：
  名称：

  Alpha-heterocyclc substituted tolunitriles

  摘要：

  该发明涉及式I的芳香化酶抑制化合物##STR1##其中R和Ro代表氢或较低的烷基；或R和Ro位于相邻的碳原子上，当与它们连接的苯环结合时形成萘或四氢萘环；R.sub.1和R.sub.2独立地代表氢、较低的烷基、(较低的烷基、芳基或芳基-较低的烷基)-硫、较低的烯基、芳基、芳基-较低的烷基、C.sub.3-C.sub.6-环烷基或C.sub.3-C.sub.6-环烷基-较低的烷基；或R.sub.1和R.sub.2结合代表较低的烷基亚甲基、单芳基或双芳基-较低的烷基亚甲基；R.sub.1和R.sub.2结合还代表C.sub.4-C.sub.6-直链烷基、较低的烷基取代的直链烷基或邻苯二甲基桥联的C.sub.2-C.sub.4-直链烷基，每个与其连接的碳原子形成相应的可选择取代或苯并5、6或7-成员环；W代表1-咪唑基、1-(1,2,4-或1,3,4)-三唑基或3-吡啶基；或W代表1-咪唑基、1-(1,2,4或1,3,4)-三唑基或3-吡啶基，其被较低的烷基取代；以及其药学上可接受的盐。

  公开号：

  US04978672A1

文献信息

• Letrozole production process
  申请人：Friedman Oded

  公开号：US20070112202A1

  公开（公告）日：2007-05-17

  Provided is a method for preparing letrozole, which includes reacting an activated bis-(4-cyanophenyl)-methane with a triazole to produce letrozole, and, optionally, purifying the letrozole. Also provided are highly pure letrozole, and a method of purifying letrozole, which method includes precipitating letrozole, e.g., by selective precipitation from a reaction mixture and/or by subjecting the letrozole to one or more crystallizations.

  提供了一种制备来曲唑的方法，该方法包括将激活的双-(4-氰基苯基)-甲烷与三唑反应以来曲唑，以及可选地纯化来曲唑。还提供了高纯度的来曲唑，以及一种纯化来曲唑的方法，该方法包括沉淀来曲唑，例如通过从反应混合物中选择性沉淀和/或将来曲唑进行一个或多个结晶。
• [EN] USE OF AN AROMATASE INHIBITOR FOR THE TREATMENT OF HYPOGONADISM AND RELATED DISEASES<br/>[FR] UTILISATION D'UN INHIBITEUR D'AROMATASE POUR LE TRAITEMENT DE L'HYPOGONADISME ET DE MALADIES APPARENTÉES
  申请人：NOVARTIS AG

  公开号：WO2013036562A1

  公开（公告）日：2013-03-14

  This invention relates to a method of increasing testosterone levels and treating hypogonadism and related diseases with the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile. The present invention further relates to a method of increasing testosterone levels and treating hypogonadism and related diseases with the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile in a particular dosing regimen. The invention also relates to pharmaceutical compositions comprising said aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, optionally in combination with other active ingredients. Furthermore, the present invention relates to kits comprising said pharmaceutical compositions together with instructions how to administer them.

  本发明涉及一种使用芳香酶抑制剂4,4'-[氟-(1-H-1,2,4-三唑-1-基)亚甲基]双苯腈来提高睾酮水平并治疗低睾酮血症及相关疾病的方法。本发明进一步涉及在特定的剂量方案下，使用芳香酶抑制剂4,4'-[氟-(1-H-1,2,4-三唑-1-基)亚甲基]双苯腈来提高睾酮水平并治疗低睾酮血症及相关疾病的方法。本发明还涉及包含所述芳香酶抑制剂4,4'-[氟-(1-H-1,2,4-三唑-1-基)亚甲基]双苯腈的药物组合物，可选地与其他活性成分结合使用。此外，本发明还涉及包含所述药物组合物以及使用说明的试剂盒。
• Contraception in female primates without affecting the menstrual cycle
  申请人：Ciba-Geigy Corporation

  公开号：US05583128A1

  公开（公告）日：1996-12-10

  The invention relates to the use of aromatase inhibitors for contraception in female primates and to a method for contraception in female primates using such substances and to the use of those substances for the preparation of pharmaceutical compositions for contraception in female primates.

  该发明涉及在雌性灵长类动物中使用芳香化酶抑制剂进行避孕，以及使用这些物质进行雌性灵长类动物避孕的方法，以及利用这些物质制备用于雌性灵长类动物避孕的药物组合物。
• .alpha.-fluoro-.alpha.-tetrazolyl-phenylmethyl derivatives useful as
  申请人：Ciba-Geigy Corporation

  公开号：US05227393A1

  公开（公告）日：1993-07-13

  Compounds of formula I ##STR1## wherein Z, R, R.sub.1, R.sub.2 and X are as defined in the description, have valuable pharmaceutical properties and are effective especially against tumours. They are prepared in a manner known per se.

  式I的化合物，其中Z、R、R₁、R₂和X如描述中定义，具有宝贵的药理特性，特别对抗肿瘤有效。它们以已知的方式制备。
• Alpha-heterocycle substituted tolunitriles
  申请人：Ciba-Geigy Corporation

  公开号：US04749713A1

  公开（公告）日：1988-06-07

  The invention is concerned with aromatase inhibiting compounds of formula I ##STR1## where R and Ro represent hydrogen or lower alkyl; or R and Ro located on adjacent carbon atoms and together when combined with the benzene ring to which they are attached form a naphthalene or tetrahydronaphthalene ring; R.sub.1 and R.sub.2 independently represent hydrogen, lower alkyl, (lower alkyl, aryl or aryl-lower alkyl)-thio, lower alkenyl, aryl, aryl-lower alkyl, C.sub.3 -C.sub.6 -cycloalkyl, or C.sub.3 -C.sub.6 -cycloalkyl-lower alkyl; or R.sub.1 and R.sub.2 combined represent lower alkylidene, mono- or di-aryl-lower alkylidene; R.sub.1 and R.sub.2 combined also represent C.sub.4 -C.sub.6 -straight chain alkylene, lower alkyl-substituted straight chain alkylene or ortho-phenylene bridged-C.sub.2 -C.sub.4 -straight chain alkylene, each forming with the carbon atom attached thereto a corresponding optionally substituted or benzo-fused 5, 6 or 7-membered ring; W represents 1-imidazolyl, 1-(1,2,4- or 1,3,4)-triazolyl or 3-pyridyl; or W represents 1-imidazolyl, 1-(1,2,4 or 1,3,4)-triazolyl or 3-pyridyl substituted by lower alkyl; and pharmaceutically acceptable salts thereof.

  本发明涉及化学式I的芳香化酶抑制化合物##STR1##其中R和Ro代表氢或较低的烷基；或R和Ro位于相邻的碳原子上，当与它们连接的苯环结合时形成萘或四氢萘环；R.sub.1和R.sub.2独立表示氢、较低的烷基、(较低的烷基、芳基或芳基-较低的烷基)-硫、较低的烯基、芳基、芳基-较低的烷基、C.sub.3 -C.sub.6 -环烷基或C.sub.3 -C.sub.6 -环烷基-较低的烷基；或R.sub.1和R.sub.2结合表示较低的烷基亚甲基、单芳基或双芳基-较低的烷基亚甲基；R.sub.1和R.sub.2结合还表示C.sub.4 -C.sub.6 -直链烷基、较低的烷基取代的直链烷基或邻苯二甲基桥联的C.sub.2 -C.sub.4 -直链烷基，每个与其连接的碳原子形成相应的可选择取代或苯并-5、6或7-成员环；W代表1-咪唑基、1-(1,2,4-或1,3,4)-三唑基或3-吡啶基；或W代表1-咪唑基、1-(1,2,4或1,3,4)-三唑基或3-吡啶基，其取代为较低的烷基；以及其药学上可接受的盐。